PT - JOURNAL ARTICLE AU - Evangelos Pavlos Myserlis AU - Marios K. Georgakis AU - Stacie L. Demel AU - Padmini Sekar AU - Jaeyoon Chung AU - Rainer Malik AU - Hyacinth I. Hyacinth AU - Mary E. Comeau AU - Guido Falcone AU - Carl D. Langefeld AU - Jonathan Rosand AU - Daniel Woo AU - Christopher D. Anderson TI - A Genomic Risk Score Identifies Individuals at High Risk for Intracerebral Hemorrhage AID - 10.1101/2022.05.05.22274399 DP - 2022 Jan 01 TA - medRxiv PG - 2022.05.05.22274399 4099 - http://medrxiv.org/content/early/2022/05/10/2022.05.05.22274399.short 4100 - http://medrxiv.org/content/early/2022/05/10/2022.05.05.22274399.full AB - Background Intracerebral hemorrhage (ICH), the most fatal form of stroke, has an estimated heritability of 29%. Applying a meta-scoring approach, we developed a genomic risk score for ICH and determined its predictive power in comparison to standard clinical risk factors.Methods Using a meta-analytic approach, we combined genome-wide association data from individuals of European ancestry for ICH and ICH-related traits in a meta-genomic risk score (metaGRS) consisting of 2.6 million variants. We tested associations with ICH and the predictive performance of the metaGRS in addition to clinical risk factors in a held-out validation dataset (842 cases and 796 controls). Furthermore, we tested associations with risk of incident ICH in the population-based UK Biobank cohort (486,784 individuals, 1,526 events, median follow-up 11.3 years).Results One SD increment in the metaGRS was significantly associated with 45% higher odds for ICH (OR 1.45; 95%CI: 1.30-1.63) in age- and sex-adjusted models and 31% higher odds for ICH (OR: 1.31, 95%CI: 1.16-1.48) in models further adjusted for clinical risk factors. The metaGRS identified individuals with almost 5-fold higher odds for ICH in the top score percentile (OR: 4.83, 95%CI: 1.56-21.2). Predictive models for ICH incorporating the metaGRS in addition to clinical predictors showed superior performance compared with clinical risk factors alone (c-index: 0.695 vs. 0.686). The metaGRS showed similar associations for both lobar and non-lobar ICH, which were independent of the known APOE risk locus for lobar ICH. In the UK Biobank, the metaGRS was associated with higher risk of incident ICH (HR: 1.15, 95%CI: 1.09-1.21). The associations were significant within both a relatively high-risk population of users of antithrombotic medications, as well as among a relatively low-risk population with a good control of vascular risk factors and no use of anticoagulants.Conclusions We developed and validated a genomic risk score that predicts lifetime risk of ICH beyond established clinical risk factors among individuals of European ancestry. Whether implementation of the score in risk prognostication models for high-risk populations, such as patients under antithrombotic treatment, could improve clinical decision making should be explored in future studies.Competing Interest StatementHIH has consulted for Acuta Capital, Novartis and Nutriglobal. JR has consulted for Consulting for Takeda Pharmaceuticals. CDA has consulted for ApoPharma and Invitae, and receives Sponsored Research Support from Bayer AG, the American Heart Association, and Massachusetts General Hospital. The other authors have nothing to disclose.Funding StatementMKG is supported by a Walter-Benjamin fellowship from the German Research Foundation (Deutsche Forschungsgemeinschaft [DFG], GZ: GE 3461/1-1) and the FöFoLe program of LMU Munich (FöFoLe-Forschungsprojekt Reg.-Nr. 1120). HIH is suported by NIH R01HL138423, R01HL156024, R01HL138423-05S1 and 1R01AG072592. GJF is supported by the NIH (K76AG059992, R03NS112859), the American Heart Association (18IDDG34280056 and 817874), and a pilot grant from the Claude D. Pepper Older Americans Independence Center at Yale (P30AG021342). JR and CDA are supported by NIH R01NS103924, U01NS069673, AHA 18SFRN34250007, and AHA-Bugher 21SFRN812095. GOCHA acknowledges funding from the NIH-National Institute of Neurologic Disorders and Stroke grants K23NS042695, R01NS059727 and 5R01NS042147, the Deane Institute for Integrative Research in Atrial Fibrillation and Stroke, the Keane Stroke Genetics Research Fund, the Edward and Maybeth Sonn Research Fund, the University of Michigan General Clinical Research Center (M01 RR000042) and a grant from the National Center for Research Resources. GERFHS acknowledges funding from the NIH grants NS36695, NS30678, and the Greater Cincinnati Foundation Grant (Cincinnati Control Cohort). The European ISGC studies acknowledge funding from the Ministerio de Sanidad y Consumo de España, Instituto de Salud Carlos III with the grants: "Registro BASICMAR" Funding for Research in Health (PI051737), "GWALA project" from Fondos de Investigación Sanitaria ISC III (PI10/02064), Fondos FEDER/EDRF Red de Investigación Cardiovascular (RD12/0042); Contract for Research Training for Professionals with Specialty (CM06100067); "Ramon y Cajal" Postdoctoral Contract and Grant from Spanish Research Networks "Red HERACLES" (RD06/ 0009) (HM-ICH); the Spanish government grants (Geno-tPA project-FIS PJ060586 and GRECAS project EC08/00137) (VHH-ICH); the Polish Ministry of Education grant N402 083934 (JUHSS); the Lund University, Region Skåne and the Swedish Medical Research Council (K2007-61X-20378-01-3, K2010-61X-20378-04-3), the Swedish Stroke Association, the Freemasons Lodge of Instruction EOS in Lund, and the King Gustaf V and Queen Victoria's foundations. Biobank services and genotyping were performed at Region Skåne Competence Centre (RSKC Malmö), Sköne university hospital, Malmö, Sweden (LUHSS); the Austrian Science Fond (FWF, P20545-P05 and P13180) and the Medical University of Graz supports the databank of the ASPS (MUC-ICH).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Boards (IRB) of Massachusetts General Hospital, Mayo Clinic (FL), University of Virginia Health System, University of Florida College of Medicine, University of Michigan Health System, Beth Israel Deaconess Medical Center approved the GOCHA study. IRBs of 16 hospital systems within a 50-mile radius from the University of Cincinnati approved the GERFHS study. The information used in the Hospital del Mar Intracerebral Hemorrhage (HM-ICH) study was collected from the prospective clinical protocols of the Hospital del Mar, which fulfilled the local ethical guidelines. The identities of the individual patients were kept anonymous. Therefore, patients signed no specific informed consent. For the Vall d'Hebron Hospital ICH (VVH-ICH) study, informed written consent was obtained from all subjects, and the local Ethics Committee approved the study. The ethics committee of the University Hospital, Krakow, Poland approved the Jagiellonian University Hemorrhagic Stroke (JUHS) Study. The Lund Stroke Register (LSR) study in Lund, Sweden was approved by the Lund University Ethics Committee. Informed consent was obtained from the prospectively included patients (or in some cases from next of kin). The UK Biobank has approval from the Northwest Multi-Center Research Ethics Committee. All participants provided written informed consent. We accessed the data following approval of an application by the UK Biobank Ethics and Governance Council (application # 36993).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study will be available from the corresponding author upon reasonable request. Single nucleotide polymorphism (SNP)-specific weights for the ICH metaGRS will be made publicly available at The Polygenic Score (PGS) Catalog (https://www.pgscatalog.org).ICHintracerebral hemorrhageGWASgenome-wide association studyGRS genomic risk scoreSNPsingle nucleotide polymorphismGOCHAGenetics of Cerebral Hemorrhage on AnticoagulationGERFHSGenetic and Environmental Risk Factors for Hemorrhagic StrokeEUR/ISGCEuropean member sites contributing to the International Stroke Genetics ConsortiumUKBBUK BiobankQCquality controlPCprincipal componentHRCHaplotype Reference ConsortiumMAFminor allele frequencyLDlinkage disequilibriumAUCarea under the receiving-operating characteristics curveCADcoronary artery diseaseAICAkaike Information CriterionHEShospital episode statisticsSBPsystolic blood pressureDBPdiastolic blood pressurePPpulse pressureWMHwhite matter hyperintensitiesCKDchronic kidney diseaseeGFRestimated glomerular filtration rateUACRurine albumin-to-creatinine ratioTCtotal cholesterolTGtriglyceridesLDLlow-density lipoproteinHDLhigh-density lipoproteinT2Dtype 2 diabetes mellitusHbA1chemoglobin A1cBMIbody mass indexWHRwaist-to-hip ratioSVSsmall vessel strokeEAeducational attainment